No Data
No Data
Express News | Biogen : Guggenheim Cuts Target Price to $165.00 From $168.00
Morgan Stanley Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $152
Healthcare Stocks Aren't a Shelter From the Tariff Storm -- Barrons.com
Morgan Stanley Adjusts Price Target on Biogen to $152 From $157, Keeps Equalweight Rating
Morgan Stanley Reaffirms Their Hold Rating on Biogen (BIIB)
Express News | Gilead Sciences Down 3%, Amgen Down 2.9%, Pfizer Down 2.7%